Artemether-lumefantrine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Plasmodium Falciparum Malaria
Conditions
Plasmodium Falciparum Malaria
Trial Timeline
Jul 1, 2002 → Feb 1, 2003
NCT ID
NCT00709969About Artemether-lumefantrine
Artemether-lumefantrine is a phase 3 stage product being developed by Novartis for Plasmodium Falciparum Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00709969. Target conditions include Plasmodium Falciparum Malaria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00386763 | Phase 3 | Completed |
| NCT00386750 | Approved | Terminated |
| NCT00709969 | Phase 3 | Completed |
Competing Products
13 competing products in Plasmodium Falciparum Malaria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KLU156 + Coartem | Novartis | Phase 3 | 77 |
| artemether:lumefantrine (2.5 mg:30 mg) | Novartis | Phase 2/3 | 65 |
| INE963 | Novartis | Phase 2 | 52 |
| KAE609 + Piperaquine Phosphate | Novartis | Phase 1 | 33 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 52 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 52 |
| Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine | Pfizer | Phase 2/3 | 64 |
| Ferroquine (SSR97193) + Placebo + artesunate | Sanofi | Phase 2 | 51 |
| Ferroquine SSR97193 + Artefenomel | Sanofi | Phase 2 | 51 |
| Artefenomel (OZ439) + Ferroquine (SSR97193) | Sanofi | Phase 2 | 51 |
| Meplazumab for Injection + Sterile normal saline (0.9%) | Pacific Biosciences | Phase 1 | 25 |